ACET at a glance
Adicet Bio Inc (ACET, SEC CIK 1720580) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 28, 2026 and Form 4 insider filings as recently as August 7, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Adicet Bio Inc (ACET) reported revenue of $5.8 million (down 46.1% from FY2024) and a net loss of $116.8 million. Diluted EPS was -$16.95.
- As of June 30, 2026, 15 institutional investment managers tracked by SignalX reported holding Adicet Bio Inc (ACET) shares worth $18.9 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $5.8M
- −46.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 15 funds
- $18.9M · +2 vs prior quarter
- Latest 10-Q
- Aug 5, 2026
- Quarterly report
SignalX for ACET
Don't miss the next ACET filing
- Alerts as it files. A push when ACET files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ACET, by share count.
- Ask anything. An AI agent that reads every ACET filing and answers with sources.
ACET alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Klickstein Lloyd | A | Aug 5, 2026 | 18,300 | - |
| Peng Katie | A | Jun 21, 2026 | 4,200 | - |
| Sinclair Andrew | A | Jun 21, 2026 | 4,200 | - |
| Chodakewitz Jeffrey | A | Jun 21, 2026 | 4,200 | - |
| Grissinger Michael | A | Jun 21, 2026 | 4,200 | - |
| DUBIN STEVE | A | Jun 21, 2026 | 4,200 | - |
| Klickstein Lloyd | A | Jun 21, 2026 | 4,200 | - |
| Aftab Blake | A | Jun 19, 2026 | 55,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $10.7M | $5.8M |
| Operating Income | -$152.0M | -$127.6M | -$122.1M |
| Net Income | - | -$117.1M | -$116.8M |
| Op. Margin | - | -1191.1% | -2113.8% |
| Net Margin | - | -1093.2% | -2021.9% |
| Balance Sheet | |||
| Total Assets | $207.3M | $220.2M | $192.4M |
| Equity | - | $186.6M | $159.2M |
| ROE | - | -62.8% | -73.4% |
| Per Share | |||
| EPS | - | $-1.33 | $-16.95 |
| Cash Flow | |||
| Operating CF | -$93.7M | -$92.4M | -$95.2M |
| CapEx | $4.5M | $1.1M | $1.7M |
Source: XBRL data in Adicet Bio Inc (ACET)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ACET share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 15 | $18.9M |
| Q1 2026 | 13 | $13.2M |
| Q4 2025 | 14 | $11.0M |
- Two Sigma Investments+53.7K (+125%)
- Citadel Advisors LLC+50.9K (+13%)
- Renaissance Technologies LLC+33.4K (+14%)
- BlackRock+25.5K (+70%)
- Dimensional Fund Advisors+20.8K (+193%)
- Morgan Stanley−1.2K (-34%)
- Northern Trust−764 (-4%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 42 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ACET filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ACET SEC filings: frequently asked questions
Which institutions hold ACET stock?
As of June 30, 2026, the largest Adicet Bio Inc (ACET) holders among the 13F filers tracked by SignalX were Franklin Resources ($5.4 million), Citadel Advisors LLC ($3.7 million), Vanguard Capital Management LLC ($3.0 million), Renaissance Technologies LLC ($2.3 million), Carlyle Group ($1.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ACET's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Adicet Bio Inc (ACET) reported revenue of $5.8 million (down 46.1% from FY2024) and a net loss of $116.8 million. Diluted EPS was -$16.95. The figures come from the XBRL data in the 10-K.
What are the latest ACET SEC filings?
Adicet Bio Inc (ACET) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 28, 2026 and a Form 4 insider filing on August 7, 2026.
What is ACET's SEC CIK number?
Adicet Bio Inc (ACET)'s SEC Central Index Key (CIK) is 1720580. EDGAR lists every ACET filing under that number.
Ask anything about ACET
The research agent reads ACET's filings, financials, insider trades and 13F holders, then answers with sources.